Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment. The company develops multi-node therapies that target the PAM (PI3K/AKT/mTOR) signaling pathway, one of the most frequently altered oncogenic pathways in cancer, with the aim of blocking cancer growth signals while also managing the nutrient supply that fuels tumors. Its lead program, PIKTOR, is an all-oral investigational combination designed to achieve deeper pathway suppression with improved tolerability by inhibiting multiple nodes simultaneously. Faeth Therapeutics leverages a data-driven discovery platform that links tumor genotypes with specific therapeutic regimens and precision metabolic interventions, including nutrition-based strategies, to modulate cancer metabolism. Headquartered in San Francisco, California, and operating as a biotechnology research company, Faeth Therapeutics plays a specialized role in the oncology market by advancing metabolism-focused treatments for solid tumors within the broader biopharmaceutical and cancer therapeutics ecosystem.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. John K. Celebi M.B.A.

Employees

29

Headquarters

Rockville, MD, United States

Website

www.faeththerapeutics.com